首页 | 本学科首页   官方微博 | 高级检索  
检索        

芪血通络片联合依达拉奉治疗急性脑梗死的临床研究
引用本文:章洁,白忠华,何文元.芪血通络片联合依达拉奉治疗急性脑梗死的临床研究[J].现代药物与临床,2020,35(9):1843-1846.
作者姓名:章洁  白忠华  何文元
作者单位:湖南中医药大学医学院, 湖南 长沙 410208;湖南省中医药防治眼耳鼻咽喉疾病与视功能保护工程技术研究中心, 湖南 长沙 410208
基金项目:国家自然科学基金资助项目(81874408);湖南省自然科学基金项目(2017JJ3246);湖南省自然科学基金项目(2016JJ6117);湖南中医药大学基础医学学科基金;湖南省教育厅优秀青年基金(19B439)
摘    要:目的 研究山楂酸对鼻咽癌CNE2细胞增殖和自噬的影响,探讨PI3K/Akt/mTOR通路在该过程中的调控作用。方法 采用CCK-8法检测不同浓度的山楂酸作用不同时间对CNE2细胞增殖的影响;MDC染色法检测不同浓度山楂酸处理CNE2细胞24 h后自噬小体的形成情况;Western blotting法检测山楂酸对CNE2细胞自噬相关蛋白及PI3K/AKT/mTOR通路关键蛋白表达的影响。结果 与溶剂对照组相比,山楂酸可以抑制CNE2细胞的增殖,而且随药物处理时间和浓度的增加,抑制效果增强(P<0.05);山楂酸能够诱导细胞自噬小体的形成,且可显著提高Atg5和LC3-II/LC3-I的表达,降低p62的表达;此外,山楂酸可抑制PI3K-p110α、p-Akt和p-mTOR的蛋白表达。结论 山楂酸可抑制鼻咽癌细胞增殖,诱导鼻咽癌细胞发生自噬,其机制与PI3K/Akt/mTOR信号通路有关,可作为治疗鼻咽癌的潜在药物研究。

关 键 词:山楂酸  自噬  鼻咽癌  PI3K/Akt/mTOR  细胞增殖
收稿时间:2019/12/23 0:00:00

Clinical study on Qixue Tongluo Tablets combined with edaravone in treatment of acute cerebral infarction
ZHANG Jie,BAI Zhong-hu,HE Wen-yuan.Clinical study on Qixue Tongluo Tablets combined with edaravone in treatment of acute cerebral infarction[J].Drugs & Clinic,2020,35(9):1843-1846.
Authors:ZHANG Jie  BAI Zhong-hu  HE Wen-yuan
Institution:College of Medicine, Hunan University of Chinese Medicine, Changsha 410208, China;Hunan Provincial Engineering and Technological Research Center for Prevention and Treatment of Ophthalmology and Otolaryngology Diseases with Chinese Medicine and Protecting Visual Function, Changsha 410208, China
Abstract:Objective To study the efficacy of Qixue Tongluo Tablets combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (100 cases) with acute cerebral infarction in Guangyuan Third People''s Hospital from January 2019 to January 2020 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mL/time, once daily. Patients in the treatment group were po administered with Qixue Tongluo Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the ability of daily living, NIHSS score, hemodynamic indexes, and the serum inflammatory factors in two groups were compared. Results After treatment, the total effective rates in the control group and the treatment group were 78.00% and 96.00%, respectively, which was significantly higher than that in the control group (P<0.05). After treatment, Barthel Index score of two groups was significantly increased, but NIHSS score was significantly decreased (P<0.05), and the Barthel Index score of the treatment group was significantly higher than that of the control group, and NIHSS score was significantly lower than that of the control group (P<0.05). After treatment, the whole blood high shear viscosity, whole blood low shear viscosity, hematocrit, and fibrinogen levels of two groups were significantly decreased (P<0.05), and the whole blood high shear viscosity, whole blood low shear viscosity, hematocrit, fibrinogen levels in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, serum levels of MDA, hs-CRP, and IL-6 in two groups were significantly decreased (P<0.05), and the serum levels of MDA, hs-CRP and IL-6 in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Qixue Tongluo Tablets combined with Edaravone Injection has clinical curative effect in treatment of acute cerebral infarction, can improve the living ability, improve hemorheology indexes, and reduce the serum level of inflammatory factors.
Keywords:maslinic acid  autophagy  nasopharyngeal carcinoma  PI3K/Akt/mTOR  cell proliferation
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号